TOP STORIES
respiratory
Lung cancer

Immune therapy benefits confirmed in NSCLC

Overall survival is doubled in patients with metastatic NSCLC  treated with pembrolizumab in combination with chemotherapy compared to chemo alone, a phase 3 trial has shown. In findings released at the American Association for Cancer Research (AACR) annual meeting in Chicago, the KEYNOTE-189 study showed significant benefits for pembrolizumab combined with pemetrexed and a platinum-based drug ...

Already a member?

Login to keep reading.


OR
© 2020 the limbic